Bellerophon Therapeutics — Investor Presentation (September 2018)
30 slides from Bellerophon Therapeutics's investor presentation, Sep 5, 2018
Slide 1: Company Presentation September 2018
Company Presentation September 2018 Nasdaq: BLPH
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation, including statements regarding our strategy, future operations, future financi
Slide 3: Bellerophon Therapeutics (BLPH) – Company Profile
Bellerophon Therapeutics (BLPH) – Company Profile Clinical-Stage Company spun-off from Ikaria Biotherapeutics Focused on developing inhaled nitric oxide (iNO) based therapies for outpatient management of chronic pulmonary diseases Company Portable, lightweight delivery system allows for chroni
Slide 4: Investment Highlights
Investment Highlights Therapeutic benefit of inhaled nitric oxide (iNO) has been demonstrated Approved for acute treatment of persistent pulmonary hypertension Proprietary INOpulse technology enables advanced clinical stage product candidate targeting several unmet indications, including multi
Slide 5: Development Pipeline
Development Pipeline Development Stage Indication Market 2017 2018 2019 Key Milestones PH-IPF • 220,000 with ILD in US Ph 2a Phase 2 Trial completed • 35-40% with • Results presented in May 2017 PH-ILD associated PH at rest Phase 2b Trial: iNO-PF (WHO Group 3) • Unmet medical need iNO-PF • Trial und
Slide 6: Highly Experienced Leadership Team
Highly Experienced Leadership Team 10 years experience as CFO at Jonathan Peacock Amgen and Novartis Pharma and Chairman 10+ years as partner in Strategy and Corporate Finance consulting Fabian Tenenbaum 15 years of executive-level Chief Executive Officer experience in finance, business development
Slide 7: INOpulse Platform Overview
INOpulse Platform Overview Novel drug-device combination Potential to target therapy with dual mechanisms multiple unmet and NO of action underserved chronic • Targeted pulmonary pulmonary diseases Nitric Oxide is a well established vasodilation including areas where vasodilator approved for acute •
Slide 8: INOpulse Provides a Unique and Differentiating Mechanism of Action
INOpulse Provides a Unique and Differentiating Mechanism of Action Baseline Hypoxic pulmonary vasoconstriction prevents oxygen desaturation Systemic Vasodilators Systemic vasodilators can reverse hypoxic vasoconstriction leading to ventilation/perfusion (V/Q) mismatch and arterial O2 desaturation IN
Slide 9: INOpulse: Portable Delivery System Allows Chronic iNO Therapy
INOpulse: Portable Delivery System Allows Chronic iNO Therapy Commercial platform sold to Mallinckrodt for R&D Platform spun-out to form Bellerophon $2.3B Therapeutics • Continuous flow iNO delivery system • Pulsatile iNO delivery system • Approved for use in persistent pulmonary • Pulsed iNO can de
Slide 10: INOpulse Delivery System: Lightweight, Portable and User Friendly
INOpulse Delivery System: Lightweight, Portable and User Friendly Drug & Battery Cannula Power Indicators Alarm Key & Connector Swing Intuitive and engagement simple user with drug interface cartridge Oxygen Sources Lightweight Tri-lumen portable cannula design allows allows direct ease of connectio
Slide 11: Differences in PH Pathology, Standard of Care, and INOpulse Mechanism of Action
Differences in PH Pathology, Standard of Care, and INOpulse Mechanism of Action PH Group 1 (PAH) PH Group 3 (PH-ILD & PH-COPD) PH Group 5 (PH-Sarc) Underlying • Vascular disease • Pulmonary disease (obstructive, • Inflammatory disease Disease fibrotic, etc.) (granulomas) PH • Normal lung function •
Slide 12: Interstitial Lung Disease (PH-ILD) Represents a Significant Unmet Medical Need
Interstitial Lung Disease (PH-ILD) Represents a Significant Unmet Medical Need Interstitial Lung Disease (ILD) is a broad category of diffuse lung diseases characterized by variable amounts of inflammation and fibrosis Idiopathic Pulmonary Fibrosis (IPF) is the largest and most serious of the ma
Slide 13: PH-ILD Significantly Reduces Survival
PH associated with Interstitial Lung Disease (PH-ILD) Significantly Reduces Survival Pulmonary hypertension as predictor of survival in IPF Approximately 40% of IPF patients exhibit symptoms of pulmonary hypertension at rest, including elevated pulmonary pressures Prognosis and survival are sign
Slide 14: PH-ILD Market Opportunity in the US
PH-ILD Market Opportunity in the US PH-ILD • 220,000 ILD patients in the US 88% of PH- • IPF represents 44% of ILD patients IPF patients • Estimated prevalence of PH is 35-40% estimated • Prevalence of PH increases with severity to be on of underlying lung disease LTOT • Patients that are asymptomat
Slide 15: Phase 2 Study Showed Immediate Benefit of iNO on Vasodilation and Hemodynamics
Phase 2 Study Showed Immediate Benefit of iNO on Vasodilation and Hemodynamics Acute phase data showed: • Statistically significant (15.3%) increase blood vessel volume as compared to baseline • Significant correlation between ventilation and vasodilation, demonstrating selective vasodilation to bet
Slide 16: Chronic iNO Treatment Provides Benefit on Oxygen Saturation and Exercise Capacity
Chronic iNO Treatment Provides Benefit on Oxygen Saturation and Exercise Capacity Chronic phase data showed: • Clinically meaningful improvement in exercise capacity and oxygen desaturation during 6MWT • Composite endpoint of oxygen saturation and exercise capacity shows consistent improvement in DS
Slide 17: Next Steps in PH-ILD
Next Steps in PH-ILD Phase 2b (iNO-PF) study initiated with Top Line Results around year end 40 subjects with pulmonary fibrosis: assessing subjects at low or intermediate/high risk of associated pulmonary hypertension at rest 8 weeks of blinded therapy (iNO 30 vs placebo) followed by open lab
Slide 18: Chronic Obstructive Pulmonary Disease (PH-COPD) Represents a Large Unmet Medical Need
Chronic Obstructive Pulmonary Disease (PH-COPD) Represents a Large Unmet Medical Need Chronic obstructive pulmonary disease (COPD) which includes chronic bronchitis and emphysema is a group of lung diseases characterized by progressive airflow obstruction and chronic airway inflammation COPD is
Slide 19: Pulmonary Hypertension Independently Predicts Reduced Survival in Moderate-to-Severe COPD
Pulmonary Hypertension Independently Predicts Reduced Survival in Moderate-to-Severe COPD COPD patients with Pulmonary 5 Year Survival Hypertension have poor prognosis mPAP < 25 mmHg: 63% mPAP ≥ 25 mmHg: 37% and QoL Median life-expectancy is ~4 years with high hospitalization mPAP < 25 mmHg rate
Slide 20: PH-COPD Market Opportunity in the US
PH-COPD Market Opportunity in the US COPD in US Prevalence: 27.8 million Diagnosed: 12.7 million (45.6%) Target US Population: PH-COPD on LTOT • Overall: 1,200,000 • Severe (Stage III/IV COPD): 900,00 Estimated prevalence of pulmonary hypertension (PH) in COPD is 27% • KOL feedback indicates high
Slide 21: Demonstrated Benefit of Pulsed iNO on Vasodilation and Hemodynamics for PH-COPD Patients
Demonstrated Benefit of Pulsed iNO on Vasodilation and Hemodynamics for PH-COPD Patients Baseline Corrected Change in Hemodynamics Vonbank et al, 2003 (Vonbank et al. 2003) • Sustained hemodynamic benefits, at three months, 2 50 PVRI (dyne PVRI(dyne s of pulsed iNO+O2 0 0 1 1 • Reduced mPAP and PVRI
Slide 22: High-Resolution CT Imaging Study Demonstrated iNO Effects on Pulmonary Vessels
High-Resolution Computed Tomography Imaging Study Demonstrated iNO effects on pulmonary vessels in PH-COPD patients Targeted Vasodilation • Acute Treatment with iNO 30 mcg/kg IBW/hr for at least 20 minutes (n=6) • No significant drop in blood oxygenation (SpO2) • All six patients showed increases in
Slide 23: COPD-007 Phase 2 Study Showed Benefit of Chronic iNO Treatment
COPD-007 Phase 2 Study Showed Benefit of Chronic iNO Treatment on Exercise Capability and Hemodynamics • Subjects who completed 4 week chronic phase on iNO 30 showed: • Statistically significant increase in 6MWD at 2 weeks and 4 weeks (+50.7m) • Statistically and clinically significant decrease in s
Slide 24: Next Steps in PH-COPD
Next Steps in PH-COPD Phase 2b study design reviewed and finalized with FDA U.S. based double-blind, placebo-controlled, study in approximately 90 PH-COPD patients Multiple endpoints to be evaluated including: . 6MWD . Right ventricular function . Time to clinical worsening . Time to clinical
Slide 25: Pulmonary Hypertension associated with Sarcoidosis Represents an Orphan Unmet Medical Need
Pulmonary Hypertension associated with Sarcoidosis (PH-Sarc) Represents an Orphan Unmet Medical Need Sarcoidosis is characterized by the growth of inflammatory cells (granulomas) most commonly in the lungs or lymphatic tissues Chest x-ray & CT of patient with PH-Sarc Prevalence of sarcoidosis is
Slide 26: INOpulse Mechanism of Action has the Potential to Provide Benefit to PH-Sarc Patients
INOpulse Mechanism of Action has the Potential to Provide Benefit to PH-Sarc Patients Systemic vasodilators exacerbate hypoxic vasoconstriction and cause hypoxemia No approved therapy for treating PH in these patients Inhaled nitric oxide has been shown to improve hemodynamics and exercise capac
Slide 27: INOpulse – Intellectual Property Protection
INOpulse – Intellectual Property Protection Patent Status Expiration Notes Method of NO US/EU: Issued Jan 2027 Covers consistent delivery of prescribed dose administration Other Territories: Issued/Pending independent of respiratory rate Breath Skipping & Pulse US: Issued Sept 2025 Covers skipping b
Slide 28: Financial Summary
Financial Summary Amount (in millions) Cash and Cash Equivalents and Marketable Securities $25.9(1) Restricted Cash $0.6(1) Debt $0(1) Shares Outstanding 57.8(1) Fully Diluted 96.8(1) Current cash runway projected to cover cost of ongoing trials and key milestones into 2019, including top line res
Slide 29: Investment Highlights
Investment Highlights Therapeutic benefit of inhaled nitric oxide (iNO) has been demonstrated Approved for acute treatment of persistent pulmonary hypertension Proprietary INOpulse technology enables advanced clinical stage product candidate targeting several unmet indications, including multi
Slide 30: Thank you
Thank you Investor Contacts: Fabian Tenenbaum Chief Executive Officer [email protected] Brian Ritchie LifeSci Advisors [email protected] 212-915-2578
Bellerophon Therapeutics — Investor Presentation (September 2018) on 6ix